Patients with COVID-19 were at increased risk of a broad range of cardiovascular disorders including cerebrovascular disorders, dysrhythmias, ischemic and non–ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disease.Īt the 12-month mark, compared with the contemporary control group, for every 1000 people, COVID-19 was associated with an extra:Ĥ5.29 incidents of any prespecified cardiovascular outcomeĢ3.48 incidents of major adverse cardiovascular events (MACEs), including myocardial infarction, stroke, and all-cause mortalityġ9.86 incidents of dysrhythmias, including 10.74 incidents of atrial fibrillationġ2.72 incidents of other cardiovascular disorders including 11.61 incidents of heart failure and 3.56 incidents of nonischemic cardiomyopathyĩ.88 incidents of thromboembolic disorders, including 5.47 incidents of pulmonary embolism and 4.18 incidents of deep vein thrombosisħ.28 incidents of ischemic heart disease including 5.35 incidents of acute coronary disease, 2.91 incidents of myocardial infarction, and 2.5 incidents of anginaĥ.48 incidents of cerebrovascular disorders, including 4.03 incidents of strokeġ.23 incidents of inflammatory disease of the heart or pericardium, including 0.98 incidents of pericarditis and 0.31 incidents of myocarditis But because the study was large, it also included almost 17 000 female patients about 37 000 Black patients and almost 8000 Latino, Asian, American Indian, Native Hawaiian, and patients of other races with COVID-19. The COVID-19 cohort, which averaged 61 years old, included 89% males and about 71% White individuals. The cohorts largely comprised older White male patients. The researchers estimated the risks and excess burden of cardiovascular outcomes per 1000 persons 12 months after COVID-19 using electronic medical record data from 3 large cohorts:ġ53 760 patients who used VHA services in 2019 and had a positive SARS-CoV-2 test result between March 1, 2020, and January 15, 2021ĥ 637 647 patients with no evidence of SARS-CoV-2 infection who used VHA services in 2019-the contemporary control groupĥ 859 411 prepandemic patients who used VHA services in 2017-the historical control group The new analysis in Nature Medicine examined a comprehensive, prespecified set of cardiovascular outcomes among patients in the US Veterans Health Administration (VHA) system who survived the first 30 days of COVID-19. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |